Literature DB >> 11851739

The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial.

R N Boyd1, F Dobson, J Parrott, S Love, J Oates, A Larson, G Burchall, P Chondros, J Carlin, G Nattrass, H K Graham.   

Abstract

Hip displacement is the second most common deformity after equinus in children with cerebral palsy (CP), and may result in dislocation, pain, fixed deformity and loss of function. We studied the combined effects of intramuscular injections of botulinum toxin type A (BTX-A) to the adductors and hamstrings and a variable hip abduction orthosis (SWASH), on gross motor function, hip displacement and progression to surgery, in a randomized clinical trial. Thirty-nine children, with bilateral spastic cerebral palsy, and mean age 3 years + 2 months (range 1 year+7 months--4 years +10 months) entered the trial. Gross Motor Function Classification System (GMFCS) levels were as follows: one child was level II, 11 were level III, 13 were level IV and 14 were level V. After concealed randomization, 20 were allocated to the control group and 19 to the intervention group. Thirty-five children completed the follow up at 1 year. The novel intervention group received up to 4.0 U BOTOX/kg/muscle, 16 U/kg/body weight every 6 months plus the use of a SWASH brace. The control group received clinical best practice comprising physiotherapy but no hip abduction bracing. Both groups showed improvements in total Gross Motor Function Measure (GMFM) score [mean 6.0% BTX-A group; 6.1% Control; 95% CI -- 6.7, 6.5 (NS)], however, there was no additional treatment effect for the study group. There were similar improvements on GMFM goal scores and GMFM-66 scores, but again no additional treatment effect was observed. Multiple regression of change in total GMFM by GMFCS classification for each group showed greater improvement in the total scores from baseline in the BTX-A/SWASH treated group than the control group. In the first year, nine children (two in the intervention group and seven in the control group) required soft tissue surgery because of progressive hip migration in excess of 40%. A longer-term follow up of a larger cohort may be required to determine the effect of the combined treatment on hip displacement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11851739     DOI: 10.1046/j.1468-1331.2001.00043.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  14 in total

Review 1.  Botulinum toxin for cerebral palsy; where are we now?

Authors:  R E Morton; J Hankinson; J Nicholson
Journal:  Arch Dis Child       Date:  2004-12       Impact factor: 3.791

Review 2.  Hip dislocation in cerebral palsy.

Authors:  Teresa Pountney; Elizabeth M Green
Journal:  BMJ       Date:  2006-04-01

3.  Effectiveness of Multilevel Botulinum Toxin A Injection with Integrated Treatment Program on Spasticity Reduction in Non-Ambulatory Young Children with Cerebral Palsy.

Authors:  Sebahat Aydil; Fatma Merih Akpinar; Evren Akpinar; Kubilay Beng; Mehmet Firat Yagmurlu
Journal:  Med Princ Pract       Date:  2019-03-06       Impact factor: 1.927

Review 4.  Botulinum toxin in children with cerebral palsy.

Authors:  Pratibha Singhi; Munni Ray
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

Review 5.  Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.

Authors:  Marissa Barlaan Lukban; Raymond L Rosales; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

6.  [Modified PemberSal osteotomy technique with lyophilized human allograft].

Authors:  C Druschel; K Heck; C Kraft; R Placzek
Journal:  Oper Orthop Traumatol       Date:  2016-09-14       Impact factor: 1.154

7.  Migration percentage and odds of recurrence/subsequent surgery after treatment for hip subluxation in pediatric cerebral palsy: a meta-analysis and systematic review.

Authors:  K N Agarwal; C Chen; D M Scher; E R Dodwell
Journal:  J Child Orthop       Date:  2019-12-01       Impact factor: 1.548

Review 8.  Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.

Authors:  Francesco C Blumetti; João Carlos Belloti; Marcel Js Tamaoki; José A Pinto
Journal:  Cochrane Database Syst Rev       Date:  2019-10-08

9.  Evaluation of a passive pediatric leg exoskeleton during gait.

Authors:  Jessica Zistatsis; Keshia M Peters; Daniel Ballesteros; Heather A Feldner; Kristie Bjornson; Katherine M Steele
Journal:  Prosthet Orthot Int       Date:  2021-04-01       Impact factor: 1.895

10.  Long-term effect of botulinum toxin A on the hip and spine in cerebral palsy: A national retrospective cohort study in Taiwan.

Authors:  Ching-Yueh Lin; Chi-Hsiang Chung; Dennis J Matthews; Heng-Yi Chu; Liang-Cheng Chen; Sung-Sen Yang; Wu-Chien Chien
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.